Abstract
Parkinson’s disease (PD) is associated with neurodegeneration of the nigrostriatal tract and is accompanied with loss of tyrosine hydroxylase (TH) and dopamine (DA). Development of neuroprotective strategies targeting PD is often undermined by lack of proper understanding of processes contributing to the pathology. In this mini review we have tried to briefly outline the involvement of TH and α-synuclein in PD. Aberrant expression of α-synuclein is toxic to dopaminergic neurons. It interacts with ubiquitin-proteasomal processing system, implicated in oxidative injury and mitochondrial dysfunction which ultimately induce neurodegenration and cell death. The contributions of DJ-1 in TH regulation have also been discussed. Brain specific TH expression with the combined use of the pegylated immunoliposome (PILs) gene transfer technology and brain specific promoters as a new approach to treat PD has also been included.
Keywords: Tyrosine hydroxylase, dopamine, nigrostriatal pathway, alpha-synuclein, neurodegeneration, Parkinson’s disease.
CNS & Neurological Disorders - Drug Targets
Title:A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
Volume: 11 Issue: 4
Author(s): Wajihullah Khan, Medha Priyadarshini, Haytham A. Zakai, Mohammad A. Kamal and Qamre Alam
Affiliation:
Keywords: Tyrosine hydroxylase, dopamine, nigrostriatal pathway, alpha-synuclein, neurodegeneration, Parkinson’s disease.
Abstract: Parkinson’s disease (PD) is associated with neurodegeneration of the nigrostriatal tract and is accompanied with loss of tyrosine hydroxylase (TH) and dopamine (DA). Development of neuroprotective strategies targeting PD is often undermined by lack of proper understanding of processes contributing to the pathology. In this mini review we have tried to briefly outline the involvement of TH and α-synuclein in PD. Aberrant expression of α-synuclein is toxic to dopaminergic neurons. It interacts with ubiquitin-proteasomal processing system, implicated in oxidative injury and mitochondrial dysfunction which ultimately induce neurodegenration and cell death. The contributions of DJ-1 in TH regulation have also been discussed. Brain specific TH expression with the combined use of the pegylated immunoliposome (PILs) gene transfer technology and brain specific promoters as a new approach to treat PD has also been included.
Export Options
About this article
Cite this article as:
Khan Wajihullah, Priyadarshini Medha, A. Zakai Haytham, A. Kamal Mohammad and Alam Qamre, A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain, CNS & Neurological Disorders - Drug Targets 2012; 11 (4) . https://dx.doi.org/10.2174/187152712800792929
DOI https://dx.doi.org/10.2174/187152712800792929 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Biomedical Consequences of Alcohol Use Disorders in the HIV-Infected Host
Current HIV Research Natural Products Homoharringtonine and Emetine Alkaloids as SARS-CoV-2 Treatment Options
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Meet Our Editorial Board Member
Reviews on Recent Clinical Trials PDZ Domain-mediated Protein Interactions: Therapeutic Targets in Neurological Disorders
Current Medicinal Chemistry Clinical Assessment of Carotid Atherosclerosis Inflammation by Positron Emission Tomography
Current Molecular Medicine Enigmas and Paradoxes: the Genetic Diversity and Prevalence of the Primate Lentiviruses
Current HIV Research New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Current Approaches in Antiviral Drug Discovery Against the Flaviviridae Family
Current Pharmaceutical Design HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design